HyperAcute-Renal Immunotherapy for Salvage Treatment of mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma
Oncologist 2019 Sep 06;[EPub Ahead of Print], AW Hahn, C Drake, SR Denmeade, Y Zakharia, BL Maughan, E Kennedy, C Link, N Vahanian, H Hammers, N AgarwalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.